Compare Symbotic Inc (SYM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs Twist Bioscience Corp — how do they compare? Symbotic Inc trades at $42.3 (market cap $5.62B), while Twist Bioscience Corp trades at $156.75 (market cap $10.32B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Symbotic Inc for 23 Days and Twist Bioscience Corp for 27 Days on average.
| SYM | TWST | |
|---|---|---|
Market Cap | $5.62B | $10.32B |
Volume | 1,339,679 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $87.30 | $205.00 |
52-Week Low | $38.22 | $25.45 |
Typical Hold Time | 23 Days | 27 Days |
Enterprise Value | $3.88B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth potential with a $22.5 billion backlog but faces profitability challenges with negative net income of -$16.94 million in 2025. Analyst consensus is positive with a $60.33 price target, though recent earnings misses and customer concentration risk remain concerns.
SYM presents a growth opportunity in warehouse automation with significant backlog and expanding market demand, but investors must weigh high valuation multiples against current profitability issues and execution risks. The stock's upside depends on successful margin expansion and diversification beyond its major customer relationship.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
